• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

VIEW 1 and VIEW 2 studies: taking a deeper dive

Video

Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.

Rahul Khurana, MD, highlights the analysis illustrating that there's a lot of variability in clinicians’ management of age-related macular degeneration, and also the treatment needs. There are some patients who need to get treated every four weeks or every eight weeks, but there are also patients that can go longer. The analysis showed that nearly half of these patients could go about 12 weeks or greater. Khurana will present his poster during a reception on July 15 at this year’s American Society of Retina Specialists meeting in New York.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
© 2024 MJH Life Sciences

All rights reserved.